TECHNOLOGY AREAS
Scientific depth for
complex biotech IP matters.
Biotech patent strategy depends on understanding the science behind the claims. FYLED supports attorney-led analysis across chemistry, biologics, genetic medicine, cell therapy, regenerative medicine, radiopharmaceuticals, and AI-native discovery.
WHY TECHNOLOGY-SPECIFIC ANALYSIS MATTERS
Every modality hides risk in a different place.
Small molecule risk may sit in structure search. Protein engineering risk may sit in function rather than sequence. Cell therapy risk may sit in manufacturing and phenotype. AI-native discovery may create more possible inventions than teams can evaluate. FYLED helps interpret these modality-specific risks in a form attorneys can use.
Chemistry & Modalities
Chemical, linker, payload, and degradation systems.
Small molecules, ADCs, protein degradation, and radiopharmaceuticals.
Biology & Genetic Medicine
Sequence, construct, mechanism, delivery, and function.
Protein engineering, RNA therapeutics, gene therapy, and CRISPR.
Living Systems & AI
Processes, cell systems, regenerative products, and AI output space.
Cell therapy, regenerative medicine, and AI-native drug discovery.
EXPLORE BY TECHNOLOGY AREA
Scientific interpretation for the technologies driving biotech IP.
Chemistry
Small Molecule Patent Analysis
When the most important molecule may be the one the search missed.
Explore small molecules →Biologics
Protein Engineering Patent Analysis
Different sequences can still create the same biological function.
Explore protein engineering →RNA
RNA Therapeutics Patent Analysis
RNA IP depends on payload, delivery, expression control, and therapeutic context.
Explore RNA therapeutics →Genetic Medicine
Gene Therapy Patent Analysis
Vector choice, payload design, tropism, and manufacturing can change the full IP picture.
Explore gene therapy →Genome Editing
CRISPR Patent Analysis
CRISPR is not one lane. It is a network of editable functions, systems, and patent thickets.
Explore CRISPR →Cell Therapy
Cell Therapy Patent Analysis
The product is not just the receptor. It is the living cellular system.
Explore cell therapy →Regenerative Medicine
Regenerative Medicine Patent Analysis
The invention is often the biological process that creates the product.
Explore regenerative medicine →Targeted Degradation
Protein Degradation Patent Analysis
The drug is not only the molecule. It is the induced interaction.
Explore protein degradation →Radiopharmaceuticals
Radiopharmaceutical Patent Analysis
The therapeutic product spans targeting vector, radionuclide, chemistry, biology, and clinical use.
Explore radiopharmaceuticals →ADCs
ADC Patent Strategy
ADC IP sits across antibody, linker, payload, target biology, manufacturing, and clinical positioning.
Explore ADCs →AI-Native Discovery
AI Drug Discovery and IP
AI can generate more potential inventions than teams can evaluate.
Explore AI-native discovery →HOW FYLED SUPPORTS THESE MATTERS
Scientific interpretation for attorney-led IP decisions.
Across each technology area, FYLED helps translate scientific complexity into practical support for freedom-to-operate, diligence, landscape analysis, competitive positioning, and sequence / mechanism interpretation.
MOVE FROM SCIENCE TO STRATEGY
Need scientific support for a complex biotech IP matter?
Start with a scientific foundation that helps counsel and life-science teams understand risk, opportunity, and competitive positioning faster.
Contact FYLED